Compare Neurocrine Biosciences Inc (NBIX) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Spotify Technology — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Spotify Technology trades at $524 (market cap $108.68B). The key difference: Spotify Technology is far larger — about 6.9× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.
| NBIX | SPOT | |
|---|---|---|
Market Cap | $15.77B | $108.68B |
Sector | Health | Media |
52-Week High | $185.50 | $738.53 |
52-Week Low | $123.10 | $412.75 |
Enterprise Value | $15.78B | $98.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Spotify (SPOT) trades at $528.64, down 2.54% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish trend in moving averages but neutral oscillators, with key support at $524 and resistance at $535. Fundamentally, the company reported strong revenue growth to $17.19B in 2025 and a net income margin of 12.87%, though it missed Q2 2026 EPS estimates. Recent news highlights a $1.5B share repurchase program expansion and initiatives to label AI-generated content.
The outlook for SPOT is supported by robust earnings growth, cash flow generation, and analyst optimism, with a consensus price target of $590.29. However, risks include premium valuation multiples, competitive pressures in audio streaming, and execution challenges in sustaining high growth rates. Investor sentiment remains positive given institutional buy ratings, but volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
